Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Keybanc Initiates Coverage On Stryker with Sector Weight Rating

Keybanc Initiates Coverage On Stryker with Sector Weight Rating

Keybanc analyst Matthew Mishan initiates coverage on Stryker (NYSE:SYK) with a Sector Weight rating.

byBenzinga Newsdesk

January 25, 2023

1 minute read

Keybanc analyst Matthew Mishan initiates coverage on Stryker (NYSE:SYK) with a Sector Weight rating.

What’s Going On With Coinbase Stock?

By Erica Kollmann

May 21, 11:57 AM

Coinbase Global, Inc. (NASDAQ:COIN) shares are moving Tuesday amid increased interest in cryptocurrency-related stocks.

BTC

HanesBrands Q2 Outlook: Adj. EPS $0.07-$0.11 Vs. $0.10 Estimate, Sales $1.335B-$1.375B Vs. $1.345B Estimate

By Benzinga Newsdesk

May 9, 7:15 AM

For second-quarter 2024, which ends on June 29, 2024, the Company currently expects: Net sales of approximately $1.335 billion to $1.375 billion, which includes projected headwinds of approximately $13.5 million from

HBI

Analyst Ratings

4 Analysts Have This to Say About RTX

By Benzinga Insights

July 26, 10:00 AM

Within the last quarter, RTX (NYSE:RTX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

RTX

SciSparc Announces Results For MitoCareX Bio With Its Drug Discovery Platform

By Benzinga Newsdesk

November 27, 9:43 AM

MitoCareX Bio has met its second milestone as part of its joint venture agreement with the CompanyTEL AVIV, Israel, Nov. 27, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty

SPRC

Keybanc Initiates Coverage On Stryker with Sector Weight Rating

Related Posts

What’s Going On With Coinbase Stock?

HanesBrands Q2 Outlook: Adj. EPS $0.07-$0.11 Vs. $0.10 Estimate, Sales $1.335B-$1.375B Vs. $1.345B Estimate

4 Analysts Have This to Say About RTX

SciSparc Announces Results For MitoCareX Bio With Its Drug Discovery Platform